A small biotech raises the price on its cancer drug by 20% this year, but will anyone notice?

Stat News

9 October 2019 - As Puma Biotechnology struggles to meet sales goals and expand usage for its all-important Nerlynx breast cancer treatment, the company has resorted to a tried-and-true tactic for boosting sales — raising prices. 

But Puma has taken a step most other drug makers have avoided recently: the wholesale price for Nerlynx not only jumped twice this year, but by 9.9% each time.

In other words, Puma has now increased the price by 20% in just nine months.

Read Stat News article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , US , Pricing